Attached files
| file | filename |
|---|---|
| EX-23.1 - EXHIBIT 23.1 - CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM - Vericel Corp | exhibit231consentofindepen.htm |
| EX-99.2 - EXHIBIT 99.2 - UNAUDITED PRO FORMA FINANCIAL INFORMATION - Vericel Corp | exhibit992unauditedproform.htm |
| EX-99.1 - EXHIBIT 99.1 - SPECIAL PURPOSE INCOME STATEMENT - Vericel Corp | exhibit991specialpurposein.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 2, 2014
VERICEL CORPORATION
(Exact name of registrant as specified in its charter)
Michigan | 001-35280 | 94-3096597 | ||
(State or other jurisdiction of | (Commission File Number) | (l.R.S. Employer Identification No.) | ||
incorporation) | ||||
64 Sidney Street | ||||
Cambridge, MA | 02139 | |||
(Address of principal executive offices) | (Zip Code) | |||
Registrant's telephone number, including area code: (800) 556-0311
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.01. Completion of Acquisition or Disposition of Assets.
Vericel Corporation (the Company), a Michigan corporation is filing this third amendment to the Current Report filed Form 8-K filed by the Company on June 2, 2014 and amended on June 16, 2014 and August 29, 2014 to provide additional financial information in connection with the acquisition by the Company of the cell therapy and regenerative medicine business (the CTRM Business) of Sanofi, a French société anonyme, which was completed on May 30, 2014.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
The Special Purpose Combined Statements of Net Assets Acquired for the CTRM Business as of March 31, 2014 (unaudited), December 31, 2013 and December 31, 2012, and the Special Purpose Combined Statements of Revenues and Direct Expenses for the three month periods ended March 31, 2014 (unaudited) and 2013 (unaudited) and for the years ended December 31, 2013 and 2012 are attached to this Form 8-K/A as Exhibit 99.1 and incorporated herein by reference.
(b) Pro Forma Financial Information.
The Pro Forma Condensed Combined Statement of Operations (unaudited) for the year ended December 31, 2014 is attached to this Form 8-K as Exhibit 99.2 and incorporated herein by reference.
(c) Exhibits
Exhibit No. | Description | |
23.1 | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm | |
99.1 | Special Purpose Combined Statements of Net Assets Acquired for the CTRM Business as of March 31, 2014 (unaudited), December 31, 2013 and December 31, 2012, and Special Purpose Combined Statements of Revenues and Direct Expenses for the three month periods ended March 31, 2014 (unaudited) and 2013(unaudited) and for the years ended December 31, 2013 and 2012. | |
99.2 | Pro Forma Condensed Combined Statement of Operations (unaudited) for the year ended December 31, 2014. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Vericel Corporation | ||||
Date: June 29, 2015 | By: | /s/ Gerard Michel | ||
Name: Gerard Michel | ||||
Title: Chief Financial Officer and Vice President Corporate Development | ||||
3